Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 55Neoplasms, Plasma Cell 22Central Nervous System Neoplasms 10Prostatic Neoplasms 9Glioblastoma 9Recurrence 8Melanoma 8Brain Neoplasms 8Neoplasms 7Gliosarcoma 7Carcinoma, Non-Small-Cell Lung 7Sarcoma 6Leukemia 6Carcinoma, Hepatocellular 6Waldenstrom Macroglobulinemia 5Myeloproliferative Disorders 5Lung Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Glioma 5Colorectal Neoplasms 5Myelodysplastic-Myeloproliferative Diseases 4Myelodysplastic Syndromes 4Lymphoma 4Liver Neoplasms 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Kidney Neoplasms 4Carcinoma, Renal Cell 4Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myelomonocytic, Chronic 3

Interventions

Thalidomide 1Prednisolone 1Methylprednisolone 1Hydrocortisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Oral Ulcer × Thalidomide × Clear all
NCT00001524 2008-03-04

Thalidomide to Treat Oral Lesions in HIV-Infected Patients

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
110 enrolled

Acquired Immunodeficiency Syndrome, Burning Mouth Syndrome, Stomatitis, Aphthous, HIV Infections, Oral Ulcer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡